Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23515735 | 0.96 | MAPT (0.58) | MAPTRXFP1TP53FOXM1LMNA | |
| SCHEMBL24107693 | 0.93 | HPGD (0.54) | MAPTRXFP1TP53FOXM1HPGD | |
| SCHEMBL21586257 | 0.88 | MAPT (0.74) | MAPTRXFP1TP53FOXM1HPGD | |
| SCHEMBL29932640 | 0.88 | MAPT (0.74) | MAPTRXFP1TP53FOXM1HPGD | |
| SCHEMBL23515691 | 0.84 | MAPT (0.71) | MAPTRXFP1TP53FOXM1HPGD | |
| SCHEMBL21589903 | 0.81 | HPGD (0.65) | MAPTRXFP1TP53FOXM1HPGD | |
| SCHEMBL25891614 | 0.79 | MAPT (0.61) | MAPTRXFP1TP53FOXM1HPGD | |
| SCHEMBL21589933 | 0.76 | HPGD (0.56) | MAPTRXFP1HPGDMEN1KMT2A | |
| SCHEMBL25891670 | 0.76 | MAPT (0.64) | MAPTRXFP1TP53FOXM1LMNA | |
| SCHEMBL29558180 | 0.75 | MAPT (1.00) | MAPTRXFP1TP53FOXM1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226027-A1 | THIENOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | UNIVERSITE TOULOUSE III - PAUL SABATIER (FR) | 2023-07-20 | — | — | US | disclosed |
| WO-2021250231-A1 | THIENOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021116389-A1 | EPAC1 INHIBITORS FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2021-06-17 | — | — | WO | disclosed |
| WO-2019234197-A1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS EPAC INHIBITORS AND THEIR PHARMACEUTICAL USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226027-A1 | THIENOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | TRPC1, SARS1, EPAS1 | MAPT 3961/4885RXFP1 4561/4885TP53 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.